Immunic (IMUX) AI Stock Analysis

• Market Cap: $133.07M
• Dividend Yield: N/A
• Average Volume (3M): 4.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: N/A
• EPS Growth: 30.16%
• Country: US
• Employees: 91
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 130,464,830
• 10 Day Avg. Volume: 8,835,921
• 30 Day Avg. Volume: 4,207,791
• PEG Ratio: 0.23
• Price to Book (P/B): -124.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.67
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.86
• 1Y Price Target: $5.50
• Price Target Upside: 439.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.33
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $0.95 ▼(-7.16% Downside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is primarily constrained by weak financial performance (no revenue, large losses, heavy cash burn, and negative equity), partially offset by constructive technical momentum and a major financing that extends the runway, though listing compliance risk remains a meaningful overhang.

Positive Factors

Financing extends runway for Phase 3 programs

The $200M upfront financing is a durable structural benefit: it materially reduces near-term refinancing pressure and explicitly funds completion of key Phase 3 MS programs into late 2027, allowing the company to advance pivotal trials without immediate reliance on capital markets.

Low absolute debt / low leverage

Historically very low debt gives Immunic flexibility to prioritize R&D spending and structure future financings with less interest burden. This durable balance sheet characteristic reduces fixed cash obligations and supports strategic optionality amid ongoing clinical development.

Advanced clinical-stage MS-focused pipeline

A concentrated pipeline with multiple Phase 3 programs for an oral DHODH inhibitor positions the company to potentially transition to commercial-stage if trials succeed. This focus and program scale are durable value drivers tied to clinical outcomes and future revenue opportunity.

Negative Factors

No revenue and sustained large net losses

Absence of revenue and persistent large losses are structural negatives: the business depends entirely on external capital to fund operations, offers no operating cash inflows to offset burn, and has no demonstrated operating leverage to narrow losses over the medium term.

Deteriorated balance sheet and negative equity

The material erosion of equity and assets is a durable weakness: it reduces the company’s financial cushion, limits borrowing capacity, increases dependence on dilutive financings, and elevates restructuring or solvency risk if development setbacks occur.

High and worsening cash burn

Sustained and increasing cash burn creates a persistent funding requirement: even with recent proceeds, the company must secure additional capital to complete development and commercialize, making dilution risk and execution dependence on future financings structural constraints.

Immunic Business Overview & Revenue Model

Company Description

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

How the Company Makes Money

Immunic makes money primarily through the development and commercialization of its drug candidates. The company focuses on advancing its pipeline through clinical trials, with the aim of achieving regulatory approval and subsequently marketing these therapies. Revenue is anticipated to be generated through direct sales, licensing agreements, and partnerships with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on sales. As a clinical-stage company, Immunic may also rely on funding from investors, grants, or other financial instruments to support its research and development activities.

Immunic Financial Statement Overview

Summary

No revenue and persistent large net losses across 2020–2025 with consistently negative operating and free cash flow. Minimal debt is a positive, but the balance sheet weakened materially with assets shrinking and stockholders’ equity turning negative by 2025, increasing financing risk.

Income Statement

Across 2020–2025 annual periods, the company reports no revenue and sustained large operating and net losses. Losses remain elevated (net loss roughly $94M–$120M from 2021–2024 and ~$97M in 2025), indicating the business is still heavily in investment mode without visible operating leverage in the provided data. A modest improvement in net loss in 2025 versus 2024 is a positive, but overall profitability and margin profile remain very weak.

Balance Sheet

Leverage is low in absolute terms (total debt is very small relative to assets historically), which is a clear strength. However, the balance sheet has deteriorated materially: stockholders’ equity fell from $184M (2020) to negative $6.7M (2025), signaling significant accumulated losses and reduced financial cushion. Total assets also declined sharply over time (from ~$168M in 2020 to ~$24M in 2025), increasing refinancing and funding risk despite low stated debt.

Cash Flow

Cash generation is consistently negative: operating cash flow is deeply negative each year (about -$46M in 2020 and around -$65M to -$86M from 2021–2025), and free cash flow is similarly negative. Cash burn worsened from 2023 to 2025, and free cash flow growth is negative in the most recent periods, implying rising funding needs. While free cash flow tracks net loss closely (suggesting losses largely reflect real cash usage rather than accounting-only items), the overall cash profile remains a key weakness.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-111.00K	0.00	0.00
EBITDA	-97.00M	-97.92M	-99.11M	-86.44M	-91.58M
Net Income	-97.17M	-100.51M	-93.61M	-120.41M	-92.94M
Balance Sheet
Total Assets	24.05M	40.87M	54.30M	127.75M	139.10M
Cash, Cash Equivalents and Short-Term Investments	15.48M	35.67M	46.67M	116.37M	86.86M
Total Debt	107.00K	1.00M	1.33M	1.56M	992.00K
Total Liabilities	107.00K	22.44M	25.37M	14.07M	11.98M
Stockholders Equity	-6.67M	18.43M	28.93M	113.68M	127.11M
Cash Flow
Free Cash Flow	-85.97M	-85.03M	-71.16M	-65.26M	-83.30M
Operating Cash Flow	-85.81M	-84.77M	-70.83M	-65.14M	-83.23M
Investing Cash Flow	-161.00K	-264.00K	9.46M	-9.74M	-67.00K
Financing Cash Flow	65.58M	74.54M	1.03M	95.76M	42.84M

Immunic Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMUX, the sentiment is Positive. The current price of 1.02 is above the 20-day moving average (MA) of 0.81, above the 50-day MA of 0.69, and above the 200-day MA of 0.79, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 69.09 is Neutral, neither overbought nor oversold. The STOCH value of 53.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMUX.

Immunic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMUX	50 Neutral	$133.07M	-1.37	-1653.15%	―	―	30.16%
EQ	50 Neutral	$110.83M	-2.88	-90.24%	―	-90.43%	-382.07%
VTVT	48 Neutral	$159.47M	-11.48	-54.87%	―	-98.30%	26.62%
ATYR	46 Neutral	$94.05M	-1.15	-103.22%	―	-19.15%	10.90%
NRXP	46 Neutral	$59.28M	-0.79	―	―	―	-9.32%
HOWL	44 Neutral	$29.13M	-0.37	-122.43%	―	-100.00%	-8.30%

Immunic Corporate Events

Immunic Secures $200M Financing to Advance MS Programs

On February 12-13, 2026, Immunic, Inc. announced an oversubscribed private placement of pre-funded warrants and common stock warrants that will deliver $200 million in upfront gross proceeds, with the potential for an additional $200 million if the warrants are exercised. The financing, led by BVF Partners and joined by a roster of prominent healthcare investors, is expected to fund completion of phase 3 ENSURE trials in relapsing multiple sclerosis, initiation of a phase 3 program in primary progressive multiple sclerosis, and operating needs into late 2027.

As part of the same financing package, Immunic agreed a royalty purchase arrangement in which holders will exchange 51,087,000 Series B warrants issued in June 2025 for a pro rata share of a 5% synthetic royalty on future sales of vidofludimus calcium, reducing outstanding warrants and aligning investors with future product revenues. Governance is also being reshaped, with Roche veteran Simona Skerjanec elevated to interim chairperson, BVF’s Thor Nagel joining the board, and a search underway for a new CEO with multiple sclerosis commercial experience, underscoring Immunic’s planned transition into a commercial-stage MS player.

The most recent analyst rating on (IMUX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.

Immunic Transfers Listing to Nasdaq Capital Market for Compliance

On January 5, 2026, Immunic, Inc. received approval to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective at the opening of trading on January 7, 2026, while continuing to trade under the symbol IMUX. The move follows a June 27, 2025 notice that Immunic had fallen out of compliance with Nasdaq’s $1.00 minimum bid price requirement and had not remedied the deficiency by the December 24, 2025 deadline; the transfer grants the company an additional 180-day grace period, until June 22, 2026, to lift its share price back above $1.00 for at least 10 consecutive business days or face potential delisting, and Immunic has informed Nasdaq it will seek to implement a reverse stock split if needed to regain compliance.

The most recent analyst rating on (IMUX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.